Objectives The aim of the study is to analyze the ALS disease progression and respiratory
function of Italian patients treated with edaravone (EVN), as well as the adherence to, and …

Introduction: Treatment with edaravone has shown efficacy in a subgroup of patients with
amyotrophic lateral sclerosis (ALS). However, it has been estimated that< 7% of ALS …

The etiology of amyotrophic lateral sclerosis (ALS) is unknown. Oxidative stress may be one
of the major mechanisms involved. In vitro and in vivo data of edaravone suggest that it may …

Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS),
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …

Aim The study aims to increase understanding of edaravone's efficacy and safety as an
amyotrophic lateral sclerosis (ALS) treatment and provide significant insights regarding this …

Importance Intravenous edaravone is approved as a disease-modifying drug for patients
with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term …

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive fatal disorder that affects all
skeletal muscles, leading to death, mostly within 2–4 years from onset. To date, the anti …

Abstract Background and Objective The efficacy and safety of edaravone for the treatment of
amyotrophic lateral sclerosis (ALS) remain unclear. The aim of this meta-analysis was to …

Abstract Background In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients
experienced significantly less physical functional decline with 24‐week edaravone vs …

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative
disease. Although the pathogenesis remains unresolved, oxidative stress is known to play a …